CSL Behring: CSL's Hemgenix receives MHRA authorisation
Treatment is the only single infusion gene therapy for the treatment of severe haemophilia B
Read full article »
CSL Behring is a Pennsylvania-based biopharmaceutical company that develops protein-based therapies for the treatment of bleeding disorders and pulmonary disease.
Read more